Prof Jesús San Miguel speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He discusses the KarMMa study initial results. KarMMa looks at idecabtagene vicleucel , a BCMA-targeted CAR T cell therapy, in patients with relapsed and refractory multiple myeloma.
Prof Miguel explains the very positive initial results, providing specific response data, and an outline of the toxicity profile.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.